
    
      This is a Phase II, multi-centre, single arm study aiming at evaluating efficacy and toxicity
      of Trabectedin in a population of advanced or recurrent ovarian and uterine carcinosarcoma.

      Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks
      via a central venous catheter.
    
  